


An Asymmetric Vinylogous Michael Cascade of Silyl Glyoximide, Vinyl Grignard, and Nitroalkenes via Long Range Stereoinduction

Gregory R. Boyce[†] and Jeffrey S. Johnson^{*‡}[†]Department of Chemistry and Physics, Florida Gulf Coast University, Fort Myers, Florida 33965, United States[‡]Department of Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599-3290, United States**S** Supporting Information

ABSTRACT: A diastereoselective auxiliary-mediated vinylation/[1,2]-Brook rearrangement/vinylogous Michael cascade of silyl glyoximide, vinylmagnesium bromide, and nitroalkenes is described. The reaction occurs with complete regio- and diastereocontrol in good yield. The diastereoselectivity is induced by a rare instance of 1,7-chirality transfer that is hypothesized to arise from a *trans*-multihetero-decalin transition state.



Vinylogous reactivity provides a distinct and atom economical approach for the direct γ -functionalization of carbonyls to synthesize complex targets. Prototypical cases involve the conversion of α,β -unsaturated carbonyls to their derived dienolates, or synthetic equivalents thereof, and electrophilic trapping at the γ -carbon. Although the vinylogous Mukaiyama aldol¹ and Mannich² reactions have become well-established, the vinylogous Michael reaction has received less attention.³ A key selectivity issue is the site of trapping in the extended π -system. Computational studies of frontier orbital densities and HOMO coefficients of simple lithium metal-dienolates have established that α -trapping is favored over the γ -position.^{1a,4} The majority of examples of the vinylogous Michael reaction rely on substrates with an inherent preference for γ -selectivity relative to α -trapping: butenolides or α,α -dicyanoalkenes are commonly used.²

Despite these challenges, some impressive examples of γ -functionalization via the vinylogous Michael reaction have been reported with various latent nucleophiles in the past five years. In 2010, Melchiorre and co-workers demonstrated that 3-alkylcyclohex-2-en-1-ones could be employed as competent nucleophiles in highly regio- and enantioselective organo-catalytic vinylogous Michael reactions with β -nitrostyrenes.⁵ Jørgenson then demonstrated the use of enals as acyclic latent dienolates in reactions with α -keto esters to construct dihydropyrans via formal [4 + 2] cycloaddition.⁶ Linear vinylogous Michael products were developed independently by Schnieder⁷ and Xu⁸ that expanded the vinylogous Mukaiyama Michael reaction (VMMR) to include aromatic α,β -unsaturated ketones with enals to provide valuable 1,7-dioxo compounds. In 2013, Wang and co-workers described (salen)Mg-catalyzed vinylogous Michael additions between β -alkyl chalcones and β -nitrostyrenes to give nitrocyclohexanols in a formal [4 + 2] cycloaddition.⁹ In general, the integration of functionality at the α -position is challenging, and the cases

described above all rely on deprotonation of a latent dienolate precursor (Figure 1).




Figure 1. Dienolate synthon: selected synthetic equivalents.

In 2010, we reported an alternative approach to the vinylogous Michael reaction by achieving the requisite dienolate via a vinylation/[1,2]-Brook rearrangement¹¹ of silyl glyoxylates. The latter are a reliable class of conjunctive reagents for the union of nucleophilic and electrophilic partners.¹⁰ The title reaction was envisioned based on the

Received: November 24, 2015

Published: February 2, 2016

seminal publications by the Kuwajima and Reich groups on silyloxyallyl- and silyloxypropargyl anionic systems.¹² Addition of vinyl Grignard¹¹ or acetylide¹³ nucleophiles to silyl glyoxylates create (*Z*)-glycolate enolates¹⁴ that can either engage a secondary electrophile with either α - or γ -trapping. The identity of the secondary electrophile employed in silyl glyoxylate couplings functions as a regiochemical switch: carbonyl electrophiles provide predominantly α -adducts,¹⁵ whereas nitroalkenes and cyanoolefins provide exclusively γ -addition via trapping of an unusual α -keto ester homoenolate synthetic equivalent. Although the vinylogous Michael methodology provided good yields and complete regioselectivity favoring the γ -adduct, the utility was limited by the lack of stereoselectivity in forming the new chiral center.

Inducing asymmetry in the three-component couplings of silyl glyoxylates has been a topic of significant interest with instructive examples highlighted in Figure 2. Useful levels of





Figure 2. Diastereoselective silyl glyoxylate couplings.

diastereoselectivity (dr 15:1) were initially realized in the tandem Oppenauer oxidation/aldol reaction using an 8-phenylmenthol auxiliary. Although this result demonstrates that a chiral auxiliary at the ester moiety can provide high levels of selectivity, the selectivity was highly substrate dependent and could not be developed to include a wider scope.¹⁶ Schmitt et al. found similar substrate dependence in the glycolate Michael reaction: 5:1 diastereoselection was imparted by the chiral auxiliary. In independent reports, Greszler et al.¹⁷ and Yao and Lu¹⁸ demonstrated that chiral electrophiles can successfully provide high levels of stereoinduction via a proposed chairlike transition state. After several of our attempts to accomplish the vinylogous Michael cascade asymmetrically with silyl glyoxylate and chiral catalysts failed, a suitable chiral auxiliary was sought to confer asymmetry. Silyl glyoximides, a new class of acyl

silanes developed by Hsung and co-workers, held promise as asymmetric conjunctive reagents.¹⁹

Herein, we describe vinylation-initiated vinylogous Michael cascades of silyl glyoximides, nitroalkenes, and vinylmagnesium bromide. This work builds upon the initial finding reported in the original three-component coupling of silyl glyoxylates, vinyl Grignard, and nitroalkenes.¹¹ The disclosed methodology affords (*Z*)-enolsilanes with complete regio- and diastereoselectivity by exploiting a rare example of long-range 1,7-chirality transfer to provide complete asymmetric induction. Compared to other vinylogous Michael methodologies, silyl glyoximides offer a conceptually distinct approach to the requisite dienolate nucleophile via a [1,2]-Brook rearrangement²⁰ that provides α -heteroatom functionality currently inaccessible through other methods (Scheme 1). The three-component coupling yields densely functionalized compounds, providing an enolsilane, nitro group, and acyl oxazolidinone²¹ in the product.


Scheme 1. Vinylmagnesium Bromide-Initiated Vinylogous Coupling of Silyl Glyoximide with Nitroalkenes



Because the synthesis of the desired silyl glyoximide **1** has been reported to provide a low yield,¹⁹ we sought to optimize the sequence (Scheme 2). We employed the aerobic oxidative carbonylation protocol of Stahl and co-workers,²² which utilized a 5-fold excess of the oxazolidinone to provide a significant increase in yield from 23 to 74%. The excess of the oxazolidinone is required to inhibit homocoupling of the TES-alkyne; however, because the excess is not consumed in the reaction, the oxazolidinone can be recovered by flash chromatography. For the subsequent oxidation of the ynamide to the imido acyl silane, the reported 5 mol % catalyst loading was examined to minimize the use of the ruthenium complex. For this substrate, the catalyst loading could be decreased from 5 to 1 mol % of ruthenium(IV) oxide hydrate without adversely affecting the yield (81%). This two-step synthesis provides a 60% overall yield of the imido acyl silane, which compares favorably to the synthesis of the original silyl glyoxylate reagent.²³

With a reliable synthesis of the primary electrophile in hand, the feasibility of the title process was investigated. An initial reaction of the imido acyl silane, β -nitrostyrene, and vinyl Grignard at -78 °C followed by warming to room temperature provided the desired three-component coupling product **3a** in 47% yield as a single diastereomer. The absolute configuration was determined by conversion to the known γ -nitroaldehyde by ozonolysis.²⁴ Analysis of the byproducts demonstrated that vinylmagnesium bromide acts as a highly discriminating nucleophile in this reaction manifold with a strong preference for the acyl silane over the nitroalkene secondary electrophile: only trace quantities of direct Grignard addition to the nitroalkene were observed. Optimization revealed that a 50%


Scheme 2. Optimized Synthesis of Silyl Glyoximide 1



excess of the nitroalkene improves the yield of the coupling to 75%. Unlike the related silyl glyoxylate coupling that required excess silyl glyoxylate to compensate for oligomerization,¹¹ the imido acyl silane coupling produces no observable oligomerization. This absence of oligomerization may be due to several factors, including the added steric bulk of the chiral auxiliary and the altered electronics of the dienolate. The (*Z*)-geometry of the enolsilane was determined by analogy to the related enolsilanes from the silyl glyoxylate vinylogous Michael cascade.¹¹ This (*Z*)-selectivity is also consistent with the homoenolate precedent set by the research groups of Reich and Kuwajima.^{12,14}

With suitable conditions in hand, an examination of the allowable steric and electronic parameters of the coupling in the nitroalkene component was undertaken. A variety of alkyl, alkenyl, aryl, and heteroaryl nitroalkenes were submitted to the reaction conditions, and the results are compiled in Table 1.

Table 1. Synthesis of (*Z*)-Enolsilanes via Three-Component Coupling



entry ^a	product	R	yield (%) ^b	dr ^c
1	3a	Ph	75	>20:1
2	3b	<i>o</i> -MeC ₆ H ₅	56	>20:1
3	3c	<i>p</i> -MeC ₆ H ₅	61	>20:1
4	3d	<i>o</i> -ClC ₆ H ₅	40	>20:1
5	3e	<i>p</i> -ClC ₆ H ₅	60	>20:1
6	3f	piperonyl	57	>20:1
7	3g	2-thienyl	54	>20:1
8	3h	2-furyl	70	>20:1
9	3i	(<i>E</i>)-CH=CHPh	69 ^d	>20:1
10	3j	Et	56	>20:1
11	3k	<i>i</i> Pr	63	>20:1
12	3l	CH ₂ <i>i</i> Pr	62	>20:1


^aAll reactions were conducted with [1]₀ = 0.1 M. ^bIsolated yield. ^cDiastereomeric ratio estimated from integration of ¹H NMR spectra of unpurified mixtures. ^dApproximately 85% purity.

The yields of three-component coupling products ranged from 40 to 75% with the ortho-substituted β -nitrostyrene substrates providing the lowest yields. Alkyl-, alkenyl-, and heteroaromatic-substituted nitroalkenes, as well as the piperonal-derived 3f and cinnamaldehyde-derived 3i, were well-tolerated. Nitro-diene 3i exhibited 1,4-selectivity in the face of potentially competing 1,6-addition, a circumstance that may provide a hint to the operative transition state of the three-component coupling (*vide infra*). All examples provided greater than 20:1 diastereoselectivity as judged by ¹H NMR spectroscopic analysis of the unpurified reaction mixture. α -Substituted Grignard reagents (e.g., 2-propenylmagnesium bromide) were

attempted, but productive three-component coupling was not observed.

With high levels of stereoselectivity for the vinylation coupling, we sought to utilize the silyl glyoximide to impart facial selectivity into the three-component alkynyl coupling previously reported by our group.¹³ Substituting the vinyl Grignard with an alkynyl Grignard was demonstrated to produce stereodefined silyloxyallenes 4 in a highly diastereoselective manner as illustrated in Scheme 3. Density

Scheme 3. Comparison of Diastereoselectivity between Silyl Glyoxylates and Silyl Glyoximides



functional theory (DFT) calculations supported a highly organized closed transition state where chelation between the nitro group and the metallodienolate enabled a fixed approach of the electrophile with respect to the (*Z*)-glyoxylate enolate. Exposing the silyl glyoximide to the reported coupling conditions provided 5 as a 1:1 mix of two (of four possible) diastereomers (as judged by ¹H NMR spectroscopic analysis of the unpurified reaction mixture).

Because 1,7-chiral induction is rare,²⁵ we sought to understand the transition state that imparts such a high level of diastereoselectivity. A chelation-controlled model for this coupling would rely on nitroalkene activation by the Lewis acidic ⁺MgBr portion of the (*Z*)-metallodienolate to guide the approach of the former. We invoked a strong coordination effect of the nitro group to the magnesium counterion in a related silyl glyoxylate coupling with acetylides that was corroborated by DFT-calculations. This coordination was further empirically supported by the inability of a poor chelator, benzyldenemalononitrile, to perform with the same level of selectivity in the reaction.¹³ The electron-rich oxazolidinone can form a six-membered chelate to the magnesium counterion to provide rigidity and enforce facial selectivity from the oxazolidinone stereocenter. The nitroalkene approach can then be directed by coordination to the Lewis acid, creating a *trans*-decalin transition state 6 as shown in Figure 3.

Significant precedent exists for such decalin transition states when multiple electronic interactions are possible.²⁶ The multiheterobicyclo[4.4.0]decane framework of the transition state relies on the electrostatic interaction between the nitrogen




Figure 3. Proposed *trans*-decalin transition state.

and the electron-dense α -position of the (*Z*)-metallo-dienolate. This orientation should also enable a stabilizing $\pi_{C=C} \rightarrow \pi_{N=O}^*$ interaction. This transition state would place the substituent of the nitroalkene into a desirable pseudoequatorial position that leads to the observed stereoisomer.

The three-component coupling of silyl glyoximide, vinylmagnesium bromide, and nitroalkenes to provide (*Z*)-enolsilanes with exceptional diastereoselectivity and good yields for a diverse substrate scope is disclosed. The high level of stereoselection arising from a long-range 1,7-chiral transfer is hypothesized to be a result of a highly organized *trans*-decalin transition state. This reactivity pattern offers a unique complement to known acyclic vinylogous Michael methodologies by providing access to α -substituted linear products with a densely functionalized core. The (*Z*)-stereochemistry of the enolsilane prevents the Henry cyclization observed by Wang and co-workers, enabling the isolation of linear vinylogous products for the first time.

EXPERIMENTAL SECTION

General Information. Proton and carbon nuclear magnetic resonance spectra (^1H and ^{13}C NMR) were recorded at 600 and 150 MHz, respectively, with solvent resonance as the internal standard (^1H NMR: CDCl_3 at 7.26 ppm; ^{13}C NMR: CDCl_3 at 77.0 ppm). ^1H NMR data are reported as follows: chemical shift, multiplicity (*s* = singlet, *d* = doublet, *dd* = doublet of doublets, *t* = triplet, *q* = quartet, *m* = multiplet), coupling constants (Hz), and integration. Mass spectra were obtained using an FT-ICR mass analyzer with electrospray ionization. TLC visualization was accomplished with UV light and/or either aqueous potassium permanganate (KMnO_4) or aqueous ceric ammonium molybdate (CAM) solution followed by heating. All reactions were carried out under an atmosphere of nitrogen in oven-dried glassware with magnetic stirring. Yield refers to isolated yield of analytically pure material. Yields are reported for a specific experiment and as a result may differ slightly from those found in the tables, which are averages of at least two experiments. Dichloromethane, tetrahydrofuran, and toluene were dried by passage through a column of neutral alumina under nitrogen prior to use.²⁷

Triethylsilyl Silyl Glyoximide (1). Sodium carbonate (118.7 mg, 1.12 mmol, 2 equiv), CuCl_2 (15.0 mg, 0.112 mmol, 0.2 equiv), and (*R*)-4-phenyloxazolidin-2-one (455.0 mg, 2.79 mmol, 5 equiv) were added to an oven-dried round-bottom flask. The reaction flask was purged with O_2 three times prior to the addition of toluene (3 mL, 0.2 M) and pyridine (0.09 mL, 1.12 mmol, 2 equiv). A balloon of O_2 was attached, and the reaction flask was placed in a preheated 70 °C oil bath. (Triethylsilyl)acetylene (0.10 mL, 0.56 mmol, 1 equiv) in toluene (3 mL, 0.2 M) was added dropwise over 6 h via syringe pump. The reaction was allowed to stir for 16 h and then cooled to room temperature and filtered through Celite. The crude mixture was concentrated in vacuo and then purified by flash chromatography with 25% EtOAc/hexanes to afford the requisite ynamide in 78% yield. The ynamide stains best with KMnO_4 and ultraviolet light. The unreacted oxazolidinone can be recovered and reused by flushing the column with 100% EtOAc. The ynamide (390.0 mg, 1.29 mmol, 1 equiv) was then treated with NaIO_4 (830.0 mg, 3.88 mmol, 3 equiv) and RuO_2 hydrate (1.7 mg, 0.013 mmol, 0.01 equiv) in a dichloromethane/acetonitrile/water (14 mL, 2/2/3 v/v) solution. The reaction was vigorously stirred for 3 h at room temperature, filtered through Celite, and concentrated in vacuo. The crude mixture was purified via silica

plug (100% dichloromethane) to afford 370.0 mg (86%) of product **1** as a yellow solid. The title compound's properties matched the reported characterization data.¹⁵

General Procedure for Synthesis of Nitroalkenes (2a–2l).^{28a} To the appropriate aldehyde (14.2 mmol) were added 2 mL of nitromethane and 25 mL of MeOH. This solution was cooled to 0 °C, and 35 mL of 1 M NaOH solution was added portionwise. The solution was allowed to stir for 2 h and warm to room temperature. The mixture was then slowly added to an aqueous 6 M HCl solution cooled to 0 °C and stirred for 15 min. The mixture was washed with dichloromethane (3 × 15 mL). The organic layers were combined, washed with brine, dried over Na_2SO_4 , and concentrated in vacuo. The crude mixture was purified by flash chromatography (10% EtOAc/hexanes) to afford the desired nitroalkene in yields ranging from 40 to 80% depending on the substrate. ^1H NMR spectral data matched those reported in the literature.²⁸

General Procedure for the Synthesis of Enolsilanes (3a–3l). The silyl glyoximide and nitroalkene were added to an oven-dried vial. The vial was then purged with N_2 , and toluene (0.1 M) was added. The resulting solution was cooled to –78 °C using an acetone/dry ice bath, and vinylmagnesium bromide was added dropwise to the solution. Once the addition was complete, the reaction was allowed to warm to room temperature and stirred for 1 h; it was then diluted with diethyl ether (5 mL) and quenched with saturated ammonium chloride (5 mL). The resulting mixture was stirred for 10 min. The layers were separated, and the aqueous layer was extracted with ethyl acetate (3 × 10 mL). The organic extracts were combined, washed with brine (5 mL), dried with magnesium sulfate, and concentrated in vacuo. The crude mixture was purified by flash chromatography (25% EtOAc/hexanes) to afford products **3a–l**.

(*R*)-3-((*S,Z*)-6-Nitro-5-phenyl-2-((triethylsilyloxy)hex-2-enoyl)-4-phenyloxazolidin-2-one (3a). The title compound was prepared according to the general procedure using imide **1** (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene **2a**^{28a} (33.6 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 57.4 mg (75%) of the product as a yellow oil. Analytical data for **3a**: IR (thin film, cm^{-1}) 3436, 3064, 3032, 2957, 2913, 2877, 1785, 1692, 1644, 1552, 1381, 1320, 1204, 1157; ^1H NMR (400 MHz, CDCl_3) δ 7.41–7.24 (m, 10H), 5.51–5.47 (m, 2H), 4.75–4.63 (m, 3H), 4.26 (dd, *J* = 8.4, 7.2 Hz, 1H), 3.70–3.62 (m, 1H), 2.71–2.55 (m, 2H), 0.97 (dd, *J* = 8, 7.6 Hz, 9H), 0.67 (q, *J* = 8 Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 165.9, 153.0, 144.6, 139.3, 137.2, 129.1, 129.0, 128.9, 127.7, 127.3, 126.4, 117.9, 79.5, 69.8, 58.5, 43.5, 29.6, 6.5, 5.2; TLC (20% EtOAc/hexanes) *R*_f 0.36; HRMS (ESI⁺) calcd for $\text{C}_{27}\text{H}_{34}\text{N}_2\text{O}_6\text{Si}+\text{Na}$, 533.2084; found, 533.2099.

(*R*)-3-((*S,Z*)-6-Nitro-5-(*o*-tolyl)-2-((triethylsilyloxy)hex-2-enoyl)-4-phenyloxazolidin-2-one (3b). The title compound was prepared according to the general procedure using imide **1** (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene **2b**^{28a} (38.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 44.0 mg (56%) of the product as a yellow oil. Analytical data for **3b**: IR (thin film, cm^{-1}) 2877, 2360, 1788, 1380, 1204, 746, 528; ^1H NMR (600 MHz, CDCl_3) 7.34–7.18 (m, 9H), 5.46–5.38 (m, 2H), 4.70–4.61 (m, 3H), 4.23–4.21 (m, 1H), 3.95–3.90 (m, 1H), 2.67–2.62 (m, 1H), 2.50–2.45 (m, 1H), 2.32 (s, 3H), 0.93–0.90 (m, 9H), 0.64–0.60 (m, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 166.0, 153.1, 144.7, 137.4, 137.1, 136.3, 131.0, 129.2, 129.0, 127.4, 126.7, 126.4, 125.5, 118.1, 79.1, 69.8, 58.5, 38.4, 29.2, 19.5, 6.6, 5.1; TLC (30% EtOAc/hexanes) *R*_f 0.51; HRMS (ESI⁺) calcd for $\text{C}_{28}\text{H}_{36}\text{N}_2\text{O}_6\text{Si}+\text{H}$, 525.2421; found, 525.2426.

(*R*)-3-((*S,Z*)-6-Nitro-5-(*p*-tolyl)-2-((triethylsilyloxy)hex-2-enoyl)-4-phenyloxazolidin-2-one (3c). The title compound was prepared according to the general procedure using imide **1** (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene **2c**^{28a} (38.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 45.0 mg (57%) of the product as a yellow oil. Analytical data for **3c**: IR (thin film, cm^{-1}) 3032, 2956, 2915, 2877, 1787, 1693, 1552, 1458, 1320, 1204, 746, 701; ^1H NMR (600 MHz, CDCl_3) 7.39–7.11 (m, 9H), 5.50–5.47 (m, 2H), 4.73–4.69 (m, 2H), 4.63–4.60 (m, 1H), 4.27–4.24 (m, 1H), 2.70–2.65 (m, 1H), 2.55–2.50 (m, 2H), 2.37 (s,

3H), 0.96–0.93 (m, 9H), 0.67–0.63 (m, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.1, 144.6, 137.4, 137.1, 136.3, 129.7, 129.2, 129.1, 127.2, 126.5, 118.4, 79.7, 69.9, 58.5, 43.3, 29.7, 21.1, 6.6, 5.1; TLC (30% EtOAc/hexanes) R_f 0.50; HRMS (ESI⁺) calcd for $\text{C}_{28}\text{H}_{36}\text{N}_2\text{O}_6\text{Si}+\text{Na}$, 547.2240; found, 547.2262.

(*R*)-3-((*S,Z*)-5-(*o*-Chlorophenyl)-6-nitro-2-((triethylsilyloxy)hex-2-enoyl)-4-phenyloxazolidin-2-one (3d). The title compound was prepared according to the general procedure using imide 1 (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene 2d^{28b} (41.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 35.0 mg (40%) of the product as a yellow oil. Analytical data for 3d: IR (thin film, cm^{-1}) 2957, 2877, 1786, 1693, 1551, 1381, 1320, 1204, 1064, 1003, 747, 699; ^1H NMR (600 MHz, CDCl_3) δ 7.40–7.23 (m, 9H), 5.46–5.40 (m, 2H), 4.79–4.70 (m, 3H), 4.25–4.19 (m, 2H), 2.69–2.63 (m, 2H), 0.92–0.89 (m, 9H), 0.63–0.59 (m, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 166.1, 153.1, 144.9, 137.1, 136.4, 134.0, 130.3, 129.2, 129.1, 128.8, 128.0, 127.4, 126.4, 126.2, 117.4, 77.6, 69.9, 58.5, 39.7, 28.0, 6.6, 5.2; TLC (30% EtOAc/hexanes) R_f 0.47; HRMS (ESI⁺) calcd for $\text{C}_{27}\text{H}_{33}\text{ClN}_2\text{O}_6\text{Si}+\text{Na}$, 567.1694; found, 567.1707.

(*R*)-3-((*S,Z*)-5-(*p*-Chlorophenyl)-6-nitro-2-((triethylsilyloxy)hex-2-enoyl)-4-phenyloxazolidin-2-one (3e). The title compound was prepared according to the general procedure using imide 1 (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene 2e^{28b} (41.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 49.0 mg (60%) of the product isolated as a yellow oil. Analytical data for 3e: IR (thin film, cm^{-1}) 2957, 2360, 1791, 1698, 1557, 1038, 700, 536; ^1H NMR (600 MHz, CDCl_3) δ 7.37–7.26 (m, 7H), 7.14 (d, $J = 9.0$ Hz, 2H), 5.45 (dd, $J = 8.4, 7.2$, 1H), 5.38 (q, 7.2 Hz, 1H), 4.72–4.68 (m, 1H), 4.61–4.59 (m, 1H), 4.27–4.24 (m, 1H), 3.61–3.56 (m, 1H), 2.60–2.50 (m, 2H), 0.92–0.89 (m, 9H), 0.61–0.59 (m, 6H); ^{13}C NMR (150 MHz, CDCl_3) δ 165.9, 153.1, 144.9, 137.8, 137.1, 133.6, 129.2, 129.2, 129.1, 128.7, 126.5, 117.2, 79.2, 69.9, 58.5, 42.9, 29.5, 6.6, 5.2; TLC (30% EtOAc/hexanes) R_f 0.50; HRMS (ESI⁺) calcd for $\text{C}_{27}\text{H}_{33}\text{ClN}_2\text{O}_6\text{Si}+\text{Na}$, 567.1694; found, 567.1710.

(*R*)-3-((*S,Z*)-5-(Benzo[d][1,3]dioxol-5-yl)-6-nitro-2-((triethylsilyloxy)hex-2-enoyl)-4-phenyloxazolidin-2-one (3f). The title compound was prepared according to the general procedure using imide 1 (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene 2f^{28c} (44.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 46.0 mg (55%) of the product as a yellow oil. Analytical data for 3f: IR (thin film, cm^{-1}) 2956, 2877, 2360, 1785, 1694, 1248, 1204, 1040, 745, 701; ^1H NMR (600 MHz, CDCl_3) δ 7.39–7.27 (m, 5H), 6.61 (d, $J = 8.4$ Hz, 1H), 6.68–6.64 (m, 2H), 5.95 (s, 2H), 5.47–5.42 (m, 2H), 4.70 (t, $J = 3.0$ Hz, 1H), 4.65–4.62 (m, 1H), 4.55–4.51 (m, 1H), 4.26–4.22 (m, 1H), 3.53–3.49 (m, 1H), 2.62–2.59 (m, 1H), 2.46–2.44 (m, 1H), 0.92–0.90 (m, 9H), 0.63–0.59 (m, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 166.0, 153.1, 148.1, 147.1, 144.7, 137.1, 133.0, 129.2, 129.1, 126.5, 120.7, 118.1, 107.5, 101.2, 79.8, 69.9, 58.5, 43.4, 29.7, 6.6, 5.1; TLC (30% EtOAc/hexanes) R_f 0.47; HRMS (ESI⁺) calcd for $\text{C}_{28}\text{H}_{34}\text{N}_2\text{O}_8\text{Si}+\text{Na}$, 577.1982; found, 577.1995.

(*R*)-3-((*R,Z*)-5-(Thiophen-2-yl)-2-((triethylsilyloxy)hex-2-enoyl)-4-phenyloxazolidin-2-one (3g). The title compound was prepared according to the general procedure using imide 1 (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene 2g^{28a} (35.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 42.0 mg (54%) of the product isolated as a yellow oil. Analytical data for 3g: IR (thin film, cm^{-1}) 2957, 2877, 2360, 1785, 1695, 1379, 1204, 1013, 744, 700; ^1H NMR (600 MHz, CDCl_3) δ 7.37–7.23 (m, 6H), 6.97–6.96 (m, 1H), 6.90 (d, $J = 3$ Hz, 1H), 5.51–5.46 (m, 2H), 4.72–4.69 (m, 2H), 4.61–4.59 (m, 1H), 3.99–3.92 (m, 1H), 2.66–2.63 (m, 2H), 0.93–0.90 (m, 9H), 0.64–0.60 (m, 6H); ^{13}C NMR (150 MHz, CDCl_3) δ 166.0, 153.1, 145.0, 142.3, 137.1, 129.2, 129.1, 127.1, 126.5, 125.3, 124.6, 117.3, 79.9, 69.9, 58.5, 39.0, 30.4, 6.6, 5.2; TLC (30% EtOAc/hexanes) R_f 0.36; LRMS (ESI⁺) calcd for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{O}_6\text{SSi}+\text{Na}$, 539.17; found, 539.26.

(*R*)-3-((*R,Z*)-5-(Furan-2-yl)-6-nitro-2-((triethylsilyloxy)hex-2-enoyl)-4-phenyloxazolidin-2-one (3h). The title compound was prepared according to the general procedure using imide 1 (50.0

mg, 0.150 mmol, 1.0 equiv), nitroalkene 2h^{28b} (32.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 49.0 mg (65%) of the product isolated as an orange oil. Analytical data for 3h: IR (thin film, cm^{-1}) 2957, 2877, 2360, 2341, 1787, 1693, 1555, 1379, 1321, 1204, 746, 700; ^1H NMR (600 MHz, CDCl_3) δ 7.37–7.30 (m, 7H), 6.32 (d, $J = 1.8$ Hz, 1H), 6.31 (d, $J = 1.8$ Hz, 1H), 6.15–6.14 (m, 1H), 5.50–5.45 (m, 3H), 4.72–4.71 (m, 1H), 4.26–4.23 (m, 1H), 2.62–2.61 (m, 2H), 0.92–0.89 (m, 9H), 0.63–0.59 (m, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 166.0, 153.2, 152.2, 144.9, 142.3, 137.0, 129.2, 129.1, 126.5, 117.7, 110.4, 107.1, 69.9, 58.5, 37.2, 27.1, 6.6, 5.1; TLC (30% EtOAc/hexanes) R_f 0.44; HRMS (ESI⁺) calcd for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{O}_7\text{Si}+\text{Na}$, 523.1876; found, 523.1893.

(*R*)-3-((*S,Z*)-5-(Nitromethyl)-7-phenyl-2-((triethylsilyloxy)hepta-2,6-dienoyl)-4-phenyloxazolidin-2-one (3i). The title compound was prepared according to the general procedure using imide 1 (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene 2i^{28b} (39.4 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 55.5 mg (69%) of the product as a yellow oil. Analytical data for 3i: IR (thin film, cm^{-1}) 2955, 2359, 1791, 1623, 1507, 1331, 1205, 742, 535; ^1H NMR (600 MHz, CDCl_3) δ 7.37–7.25 (m, 10H), 6.98 (d, $J = 16.2$ Hz, 1H), 6.09–6.08 (m, 1H), 5.60–5.57 (m, 1H), 5.48–5.42 (m, 1H), 4.71 (t, $J = 3.0$ Hz, 1H), 4.53–4.52 (m, 1H), 4.52 (d, $J = 9.0$ Hz, 1H), 4.26–4.24 (m, 1H), 2.45–2.34 (m, 1H), 2.46–2.42 (m, 1H), 0.90–0.89 (m, 9H), 0.63–0.59 (m, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 166.1, 153.2, 144.7, 137.1, 136.3, 133.3, 129.2, 129.1, 128.6, 127.9, 127.1, 126.5, 118.1, 79.0, 69.9, 58.6, 41.7, 28.4, 6.7, 5.1; TLC (30% EtOAc/hexanes) R_f 0.47; HRMS (ESI⁺) calcd for $\text{C}_{29}\text{H}_{36}\text{N}_2\text{O}_6\text{Si}+\text{Na}$, 559.2240; found, 559.2255.

(*R*)-3-((*R,Z*)-5-(Nitromethyl)-2-((triethylsilyloxy)hept-2-enoyl)-4-phenyloxazolidin-2-one (3j). The title compound was prepared according to the general procedure using imide 1 (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene 2j^{28c} (23.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 35.0 mg (51%) of the product isolated as a clear oil. Analytical data for 3j: IR (thin film, cm^{-1}) 2959, 2877, 1789, 1696, 1002, 744, 700, 533; ^1H NMR (600 MHz, CDCl_3) δ 7.40–7.33 (m, 5H), 5.60–5.57 (m, 1H), 5.50–5.47 (m, 1H), 4.72 (t, $J = 9$ Hz, 1H), 4.38–4.32 (m, 2H), 4.28–4.25 (m, 1H), 2.40–2.17 (m, 3H), 1.45 (q, $J = 7.2$ Hz, 2H), 0.98–0.89 (m, 12H), 0.63–0.59 (m, 6H); ^{13}C NMR (150 MHz, CDCl_3) δ 166.1, 153.3, 144.6, 137.1, 129.2, 129.1, 126.4, 119.3, 78.6, 69.8, 58.6, 39.1, 26.9, 24.4, 10.8, 6.6, 5.2; TLC (20% EtOAc/hexanes) R_f 0.32; HRMS (ESI⁺) calcd for $\text{C}_{23}\text{H}_{34}\text{N}_2\text{O}_6\text{Si}+\text{Na}$, 485.2084; found, 485.2092.

(*R*)-3-((*S,Z*)-6-Methyl-5-(nitromethyl)-2-((triethylsilyloxy)hept-2-enoyl)-4-phenyloxazolidin-2-one (3k). The title compound was prepared according to the general procedure using imide 1 (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene 2k^{28c} (29.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 34.5 mg (71%) of the product as a pale yellow oil. Analytical data for 3k: IR (thin film, cm^{-1}) 2459, 2877, 2360, 1788, 1693, 1550, 1383, 1205, 1004, 745, 700; ^1H NMR (600 MHz, CDCl_3) δ 7.40–7.33 (m, 5H), 5.60–5.58 (m, 1H), 5.50–5.47 (m, 1H), 4.36–4.34 (m, 1H), 4.31–4.25 (m, 3H), 2.39–2.15 (m, 3H), 1.88–1.68 (m, 1H), 0.95–0.88 (m, 15H), 0.62–0.58 (m, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 166.1, 153.3, 144.7, 137.0, 129.2, 129.1, 126.5, 120.3, 69.9, 58.7, 41.7, 28.4, 6.7, 5.1; TLC (30% EtOAc/hexanes) R_f 0.59; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{36}\text{N}_2\text{O}_6\text{Si}+\text{H}$, 477.2421; found, 477.2451.

(*R*)-3-((*R,Z*)-7-Methyl-5-(nitromethyl)-2-((triethylsilyloxy)oct-2-enoyl)-4-phenyloxazolidin-2-one (3l). The title compound was prepared according to the general procedure using imide 1 (50.0 mg, 0.150 mmol, 1.0 equiv), nitroalkene 2l^{28b} (29.0 mg, 0.225 mmol, 1.5 equiv), and vinylmagnesium bromide (0.23 mL, 0.230 mmol, 1.5 equiv), affording 45.0 mg (62%) of the product isolated as a clear oil. Analytical data for 3l: IR (thin film, cm^{-1}) 2957, 2876, 1787, 1693, 1383, 1205, 745, 700; ^1H NMR (600 MHz, CDCl_3) δ 7.40–7.33 (m, 5H), 5.59 (t, $J = 13.0$ Hz, 1H), 4.82 (dd, $J = 8.4, 7.8$ Hz, 1H), 4.72 (t, $J = 9.0$ Hz, 1H), 4.36–4.25 (m, 3H), 2.41–2.38 (m, 2H), 2.18–2.16 (m, 1H), 1.67–1.66 (m, 1H), 1.38–1.15 (m, 2H), 0.92–0.89 (m, 15H), 0.63–0.59 (m, 6H); ^{13}C NMR (150 MHz, CDCl_3) δ 166.1, 153.2, 144.6, 137.2, 129.2, 129.0, 126.4, 119.1, 79.1, 69.8, 58.6, 40.9, 35.5,

27.6, 25.1, 22.7, 22.3, 6.7, 6.6, 5.2, 5.2; TLC (20% EtOAc/hexanes) R_f 0.39; HRMS (ESI⁺) calcd for C₂₅H₃₈N₂O₆Si+H, 491.2577; found, 491.2600.

(S)-4-Nitro-3-phenylbutanal. A 20 mL scintillation vial was charged with **3a** (35 mg, 0.069 mmol, 1.0 equiv) and CH₂Cl₂ (1.0 mL, 0.07 M). Ozone was bubbled through the solution at -78 °C until the solution turned a light blue. The reaction was then purged with N₂ for 15 min until the color dissipated. Dimethyl sulfide (0.08 mg, 0.135 mmol, 5.0 equiv) was added to the reaction mixture and warmed to room temperature. Once the reaction was complete, the solution was diluted with CH₂Cl₂ (5 mL) and H₂O (5 mL). The layers were separated, and the aqueous layer was extracted with methylene chloride (3 × 5 mL). The combined organic extracts were washed with brine (5 mL), dried with sodium sulfate, and concentrated in vacuo. The crude mixture was purified by flash chromatography (30% EtOAc/hexanes) to provide 13.4 mg (52%) of the product as a colorless oil. ¹H NMR spectral data matched those reported for the title compound;^{24a} [α]_D -24 (c 0.71, CHCl₃).

(S)-4-Nitro-3-phenylbutan-1-ol. A 20 mL scintillation vial was charged with **3a** (14 mg, 0.027 mmol, 1.0 equiv) and CH₂Cl₂ (1.0 mL, 0.03 M). Ozone was bubbled through the solution at -78 °C until the solution turned a light blue. The reaction was then purged with N₂ for 15 min until the color dissipated. NaBH₄ (3.11 mg, 0.082 mmol, 3.0 equiv) was added, and the reaction was warmed to room temperature. Once the reaction was complete, the solution was diluted with CH₂Cl₂ (5 mL) and H₂O (5 mL). The layers were separated, and the aqueous layer was extracted with methylene chloride (3 × 5 mL). The combined organic extracts were washed with brine (5 mL), dried with sodium sulfate, and concentrated in vacuo. The crude mixture was purified by flash chromatography (30% EtOAc/hexanes) to provide 4 mg (75%) of the product as a colorless oil. ¹H NMR spectral data matched those reported for the title compound.^{24b} SFC analysis showed a 96:4 er for the product.

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02693.

Copies of the ¹H and ¹³C NMR spectra and HPLC traces (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: jsj@unc.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The project described was supported by Award No. R01 GM084927 from the National Institute of General Medical Sciences.

■ REFERENCES

- (1) (a) Denmark, S. E.; Heemstra, J. R.; Beutner, G. L. *Angew. Chem., Int. Ed.* **2005**, *44*, 4682–4698. (b) Kalesse, M.; Cordes, M.; Symkenberg, G.; Lu, H.-H. *Nat. Prod. Rep.* **2014**, *31*, 563–594.
- (2) Casiraghi, G.; Battistini, L.; Curti, C.; Rassu, G.; Zanardi, F. *Chem. Rev.* **2011**, *111*, 3076–3154.
- (3) Schneider, C.; Abels, F. *Org. Biomol. Chem.* **2014**, *12*, 3531–3543.
- (4) Fukui, K.; Yonezawa, T.; Nagata, C.; Shingu, H. *J. Chem. Phys.* **1954**, *22*, 1433–1442.
- (5) Bencivenni, G.; Galzerano, P.; Mazzanti, A.; Bartoli, G.; Melchiorre, P. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 20642–20647.
- (6) Albrecht, L.; Dickmeiss, G.; Weise, C. F.; Rodríguez-Esrich, C.; Jørgensen, K. A. *Angew. Chem., Int. Ed.* **2012**, *51*, 13109–13113.

(7) (a) Gupta, V.; Sudhir, V. S.; Mandal, T.; Schneider, C. *Angew. Chem., Int. Ed.* **2012**, *51*, 6739–6742. (b) Basu, S.; Gupta, V.; Nickel, J.; Schneider, C. *Org. Lett.* **2014**, *16*, 274–277.

(8) Gu, Y.; Wang, Y.; Yu, T.-Y.; Liang, Y.-M.; Xu, P.-F. *Angew. Chem., Int. Ed.* **2014**, *53*, 14128–14131.

(9) Yang, D.; Wang, L.; Han, F.; Zhao, D.; Zhang, B.; Wang, R. *Angew. Chem., Int. Ed.* **2013**, *52*, 6739–6742.

(10) (a) Boyce, G. R.; Greszler, S. N.; Johnson, J. S.; Linghu, X.; Malinowski, J. T.; Nicewicz, D. A.; Satterfield, A. D.; Schmitt, D. C.; Steward, K. M. *J. Org. Chem.* **2012**, *77*, 4503–4515. (b) Boyce, G. R.; Johnson, J. S. *tert-Butyl 2-(tert-butyldimethylsilyl)-2-oxoacetate*. *e-EROS Encyclopedia of Reagents for Organic Synthesis*; John Wiley and Sons Ltd., 2013.

(11) Boyce, G. R.; Johnson, J. S. *Angew. Chem., Int. Ed.* **2010**, *49*, 8930–8933.

(12) (a) Kuwajima, I.; Kato, M. *J. Chem. Soc., Chem. Commun.* **1979**, 708–709. (b) Reich, H. J.; Olson, R. E.; Clark, M. C. *J. Am. Chem. Soc.* **1980**, *102*, 1423–1424. (c) Kuwajima, I.; Kato, M. *Tetrahedron Lett.* **1980**, *21*, 623–626. (d) Enda, J.; Matsutani, T.; Kuwajima, I. *Tetrahedron Lett.* **1984**, *25*, 5307–5310. (e) Kato, M.; Mori, A.; Oshino, H.; Enda, J.; Kobayashi, K.; Kuwajima, I. *J. Am. Chem. Soc.* **1984**, *106*, 1773–1778. (f) Enda, J.; Kuwajima, I. *J. Am. Chem. Soc.* **1985**, *107*, 5495–5501. (g) Matsuoka, R.; Horiguchi, Y.; Kuwajima, I. *Tetrahedron Lett.* **1987**, *28*, 1299–1302.

(13) Boyce, G. R.; Liu, S.; Johnson, J. S. *Org. Lett.* **2012**, *14*, 652–655.

(14) Schmitt, D. C.; Johnson, J. S. *Org. Lett.* **2010**, *12*, 944–947.

(15) Nicewicz, D. A.; Johnson, J. S. *J. Am. Chem. Soc.* **2005**, *127*, 6170–6171.

(16) Satterfield, A. D. Ph.D. Thesis. University of North Carolina, Chapel Hill, NC, 2009.

(17) Greszler, S. N.; Malinowski, J. T.; Johnson, J. S. *J. Am. Chem. Soc.* **2010**, *132*, 17393–17395.

(18) (a) Yao, M.; Lu, C.-D. *Org. Lett.* **2011**, *13*, 2782–2785. (b) Jiang, J.-L.; Yao, M.; Lu, C.-D. *Org. Lett.* **2014**, *16*, 318–321.

(19) Al-Rashid, Z. F.; Johnson, W. L.; Hsung, R. P.; Wei, Y.; Yao, P.-Y.; Liu, R.; Zhao, K. *J. Org. Chem.* **2008**, *73*, 8780–8784.

(20) Brook, A. G. *Acc. Chem. Res.* **1974**, *7*, 77–84.

(21) Evans, D. A.; Kim, A. S. (S)-4-Benzyl-2-Oxazolidinone *e-EROS Encyclopedia of Reagents for Organic Synthesis*; John Wiley and Sons Ltd., 2001.

(22) Hamada, T.; Ye, X.; Stahl, S. S. *J. Am. Chem. Soc.* **2008**, *130*, 833–835.

(23) Nicewicz, D. A.; Brétéché, G.; Johnson, J. S. *Org. Synth.* **2008**, *85*, 278–286.

(24) The Supporting Information contains a more detailed explanation of the stereochemical determination and enantiomeric ratio. (a) Gotoh, H.; Ishikawa, H.; Hayashi, Y. *Org. Lett.* **2007**, *9*, 5307–5309. (b) Palomo, C.; Landa, A.; Mielgo, A.; Oiarbide, M.; Puente, A.; Vera, S. *Angew. Chem., Int. Ed.* **2007**, *46*, 8431–8435.

(25) Mikami, K.; Shimizu, M.; Zhang, H.-C.; Maryanoff, B. E. *Tetrahedron* **2001**, *57*, 2917–2951.

(26) (a) McNulty, J.; Mo, R. *Chem. Commun.* **1998**, 933–934. (b) Robertson, J.; Hall, M. J.; Green, S. P. *Org. Biomol. Chem.* **2003**, *1*, 3635–3638. (c) Bliidi, L. E.; Assaf, Z.; Bres, F. C.; Veschambre, H.; Théry, V.; Bolte, J.; Lemaire, M. *ChemCatChem* **2009**, *1*, 463–471.

(27) Alaimo, P. J.; Peters, D. W.; Arnold, J.; Bergman, R. G. *J. Chem. Educ.* **2001**, *78*, 64.

(28) (a) Trost, B. M.; Müller, C. *J. Am. Chem. Soc.* **2008**, *130*, 2438–2439. (b) Sekikawa, T.; Kitaguchi, T.; Kitaura, H.; Minami, T.; Hatanaka, Y. *Org. Lett.* **2015**, *17*, 3026–3029. (c) Guo, C.; Xue, M.-X.; Zhu, M.-K.; Gong, L.-Z. *Angew. Chem., Int. Ed.* **2008**, *47*, 3414–3417.